SCHEMBL26320640

SCHEMBL26320640

CC1(C)OC2[C@@H](O1)[C@@H](CO)O[C@H]2n1ccc(N)nc1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.63
MTOR P42345 2/20 0.63
THRB P10828 1/20 0.63
MDM2 Q00987 1/20 0.63
NCOA1 Q15788 1/20 0.63
NCOA3 Q9Y6Q9 1/20 0.63
PDE3A Q14432 3/20 0.54
PDE4D Q08499 1/20 0.54
SLC29A1 Q99808 1/20 0.54
PI4KA P42356 1/20 0.52
PI4K2B Q8TCG2 1/20 0.52
PI4K2A Q9BTU6 1/20 0.52
PI4KB Q9UBF8 1/20 0.52
CACNA1F O60840 2/20 0.46
ALB P02768 2/20 0.46
MAPT P10636 2/20 0.46
CACNA1D Q01668 2/20 0.46
CACNA1S Q13698 2/20 0.46
CACNA1C Q13936 2/20 0.46
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13003005 1.00 LMNA (0.63) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20668731 1.00 LMNA (0.63) LMNAMTORTHRBMDM2NCOA1
SCHEMBL9467302 1.00 LMNA (0.63) LMNAMTORTHRBMDM2NCOA1
SCHEMBL18671585 0.88 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL4384095 0.86 LMNA (0.49) LMNAMTORTHRBMDM2NCOA1
SCHEMBL9755548 0.85 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24829322 0.84 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20668803 0.84 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL26320741 0.84 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24353169 0.83 LMNA (0.47) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293566-A1 N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto EMORY UNIVERSITY 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293566-A1 N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto TYMP, ADA, CDA LMNA 1415/4885MTOR 3720/4885THRB 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.